SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ionis Pharmaceuticals, Inc. (IONS)

NEW YORK, March 6, 2017

The investigation concerns whether Ionis and certain of its officers and/or directors have issued materially misleading business information to the investing public.

On March 6, 2017, pre-market, Ionis's subsidiary Akcea Therapeutics revealed data from a Phase 3 study of volanesorsen, an experimental therapy for familial chylomicronemia syndrome, exposing that 10 of the 66 patients that were involved in the study had discontinued treatment.  Half of the patients who discontinued the therapy was due to the injection site reactions, and the other half discontinued due to platelet declines.  Ionis reported eight serious adverse events associated with volanesorsen.  Following this news, Ionis stock dropped as much as $4.55 per share, or 8.32%, during intraday trading on March 6, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Ionis, you can assist this investigation by visiting the firm's site: www.bgandg.com/ions. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com